203 results about "Akkermansia" patented technology

The invention provides isolated Ackermansiella muciniphila, a composition containing the same and an anti-aging and / or anti-oxidation application of the Ackermansiella muciniphila. The Akkermansia muciniphila has the advantages that the average life and the longest life of the Akkermansia muciniphila in a nematode model can be prolonged, the movement activity, the swallowing function and the reproductive capacity of the Akkermansia muciniphila can be improved, the expression of insulin / IGF-1 pathway genes (daf-16, daf-2 and age-1), the expression of antioxidant genes (gst-4 and sod-3) and the expression of longevity related genes (sir-2.1) of the Akkermansia muciniphila can be up-regulated, and the antioxidant capacity and the heat stress tolerance of the Akkermansia muciniphila can be enhanced. It is shown that the Akkermansia muciniphila provided by the invention can be used for preparing or developing the anti-oxidation and anti-aging products, and the anti-oxidation and anti-aging products can be prepared from the Akkermansia muciniphila. The invention provides an efficient and safe solution for anti-aging and / or anti-oxidation.

The application belongs to the field of intestinal microbiology, and discloses a new mucinophilic Akkermansia with improved obesity and glycolipid metabolism, wherein the mucinophilic Akkermansia strain is Akk-101 and AMY001. The preservation number of Akk-101 is CGMCC No. 40786, and the preservation number of AMY001 is CGMCC No. 46141. The Akk-101 and AMY001 strains in the application are different from standard strains in nucleotide consistency and physiological and biochemical indexes, have better acid-base tolerance and colonization capacity than the standard strains, can more effectively inhibit the accumulation of liver cell lipids, reduce the fat deposition in nematodes, and have the effects of weight loss and improvement of glycolipid metabolism, so that related products can be effectively developed based on the strains.

The invention relates to the technical field of microorganisms, in particular to a culture medium and a method for culturing Ackermania muciniphila for activating Amuc-1260 by using lambda-carrageenan as a carbon source, according to the culture method, the lambda-carrageenan is used for replacing a traditional carbon source, thallus growth and proliferation can be remarkably promoted, the effect is optimal under the condition of 2.00 g / L, and the culture cost is low. Compared with the conventional carbon source (glucose), the carbon source is improved by 92.91%. Further research finds that the lambda-carrageenan can induce the Akk bacteria to up-regulate the expression of glycoside hydrolase such as Amuc-1260 and enhance the activity of pathways such as glycosaminoglycan degradation, amino acid metabolism and insulin signals, so that the metabolic adaptability and energy utilization efficiency of the bacteria are improved. Meanwhile, the Akk bacteria secrete more functional short-chain fatty acids such as acetic acid, propionic acid and the like under the condition, and have the effects of regulating intestinal health and maintaining metabolic homeostasis. The invention provides a new theoretical basis and technical support for large-scale culture of Akk bacteria and development of a metabiotic product.

The invention relates to application of Ackermania muciniphila Akk09 in preparation of an element absorption enhancer and a product of the Ackermania muciniphila Akk09, belonging to the technical field of microorganisms. The invention provides application of Akkermansia muciniphila Akk09 with the preservation number of CCTCC (China Center For Type Culture Collection) NO: M 20242401 in preparation of an element absorption enhancer and in preparation of a medicine for treating element deficiency, and further provides the Akkermansia muciniphila Akk09 containing the Akkermansia muciniphila Akk09 and the medicine for treating the element deficiency based on the application. The Akk09 provided by the invention can effectively promote the transport of iron ions, zinc ions and selenium ions and enhance the absorption of iron, zinc and selenium ions.

The invention discloses an Akkermansia massiliensis LTA21F2 strain and an application of the Akkermansia massiliensis LTA21F2 strain, and belongs to the technical field of microorganisms. The strain is preserved in the Guangdong Microbial Culture Collection Center on December 04, 2022, the preservation address is the 5th floor of the building 59, No.100 Courtyard, Xianlie Middle Road, Guangzhou, and the preservation number is GDMCC No: 63035. The Akkermansia massiliensis anaerobic fermentation bacterial liquid provided by the invention is high in viable count and strong in oxygen tolerance, still has a survival rate of more than 90% after being exposed in air for 12 hours, the viable count in a sample is increased by 25.26% after being stressed by 1.5 M H2O2 for 2 hours, and the strain has a section of characteristic sequence which can be used as a specific molecular marker, and has the characteristics of high growth rate, high viable count and the like when being subjected to enlarged culture in a 200L fermentation tank.

The present invention is based on the demonstration that bacteria of the Akkermansia genus improve the response to CAR T-cells therapy. According to the invention, Akkermansia bacteria are administered to patients treated with CAR T-cells, especially if their gut microbiome was devoid of such bacteria before administering said CAR T-cells.

The present invention relates to the use of Akkermansia muciniphila in preparing a pharmaceutical composition or a health product composition for improving metabolic syndrome, wherein the Akkermansia muciniphila is Akkermansia muciniphila AM06, Akkermansia muciniphila AM02 or a combination thereof; wherein the deposit number of Akkermansia muciniphila AM06 is CGMCC No.22793, and the deposit number of Akkermansia muciniphila AM02 is CGMCC No.22794. Improving metabolic syndrome includes preventing and / or treating metabolic syndrome. In the application, the obesity degree and insulin resistance of rats can be reduced, blood pressure can be regulated, blood sugar and blood lipid metabolism can be improved, and metabolic syndrome can be effectively prevented and treated. It also relates to the use of a composition containing the Akkermansia muciniphila in preparing or using a medicine for preventing and treating metabolic syndrome or in preparing or using a health food for improving metabolic syndrome.

The invention belongs to the technical field of biological medicine and analysis, and provides an esophageal cancer early screening model based on oral microorganisms and a construction method thereof. The model is an oral cavity microbial flora as follows: Prevotella, Granulicalala, Rothia, Prevotella, Blauria, Abiotrophia, Peptostreptococcus, Actinomycetes, Burkholderia, Akkermansia, Fudania, Kineothrix, Bacillus, Duncaniella, and Eisenbergiella, and the oral cavity microbial flora is selected from the group consisting of the following microbial flora: the oral cavity microbial flora, the oral cavity microbial flora, the oral cavity microbial flora, the oral cavity microbial flora, the oral cavity microbial flora, the oral cavity microbial flora, the oral cavity microbial flora, the oral cavity microbial flora, the oral cavity microbial flora, the oral cavity microbial flora, the oral cavity microbial flora and the oral cavity microbial flora. By identifying non-invasive biomarkers, early-stage asymptomatic esophageal cancer patients can be found.

The invention discloses lactobacillus mucus YF28 and application thereof, and belongs to the technical field of microorganisms. The fermented lactobacillus mucus YF28 is separated from Hu sheep manure, is classified and named as the fermented lactobacillus mucus YF28, and has the preservation number of CCTCC (China Center For Type Culture Collection) NO: M 20252433. The fermented lactobacillus mucilaginosus YF28 has good tolerance in the gastrointestinal environment and can reach the intestinal tract to play a role. The bacterial strain has strong intestinal adhesion capacity, is easy to form a probiotic biological membrane, and is beneficial to intestinal health. The fermented lactobacillus mucus YF28 can promote peristalsis, enrich the abundance of Akkermansia bacteria and bacteriophage thereof, restore the water content of excrement to a normal level, and significantly promote intestinal health. The invention has an application prospect in the development of drugs or health-care foods with the function of relieving constipation and related gastrointestinal symptoms.

The invention relates to the technical field of probiotic preparations, in particular to an Ackerman bacterium probiotic preparation and application of the Ackerman bacterium probiotic preparation in prevention of bacterial pneumonia of chicks, the Ackerman bacterium probiotic preparation is prepared from the following raw materials in parts by weight: 40-60 parts of compound probiotics, 10-25 parts of prebiotics, 10-18 parts of a carrier and 8-15 parts of a freeze-drying protective additive, the preparation method of the Ackerman bacteria probiotic preparation comprises the following steps: adding the prebiotics and the freeze-drying protective agent into sterile water, and uniformly stirring to prepare a mixed solution; and fully mixing the composite probiotics with the mixed solution and the carrier, performing freeze drying, controlling the water content to be 3-5% after drying, and performing granulation to obtain the Ackerman bacteria probiotic preparation. The Ackerman bacterium probiotic preparation can significantly reduce the morbidity and mortality of bacterial pneumonia of chicks, and provides a new efficient and green disease prevention and control strategy for the poultry breeding industry.

Provided herein are methods and compositions related to reducing appetite. In some aspects, provided herein are methods of reducing appetite in a subject by administering to the subject a composition comprising Parabacteroides and Akkermansia bacteria.

The invention discloses a composition for treating hyperuricemia nephropathy and application thereof, and belongs to the field of biological medicines.The composition is prepared from, by weight, 28-32 parts of rhizoma smilacis glabrae, 28-32 parts of yam rhizome, 13-17 parts of radix clematidis, 8-12 parts of peach kernels, 8-12 parts of flos carthami, 8-12 parts of herba lycopi, 18-22 parts of rhizoma alismatis, 28-32 parts of raw coix seeds, 28-32 parts of semen plantaginis, 13-17 parts of rhizoma atractylodis and 13-17 parts of pseudobulbus cremastrae seu pleiones. The composition can obviously reduce the uric acid level of a mouse with high uric acid nephropathy and improve kidney injury; meanwhile, intestinal flora of mice with the hyperuricemia nephropathy can be remarkably remodeled, abundance of beneficial bacteria Ackerman's bacteria is up-regulated, abundance of opportunistic pathogenic bacteria such as escherichia coli-shigella, desulfurization vibrio and enterococcus is down-regulated, and important significance is achieved for research and drug development of the hyperuricemia nephropathy.

The disclosure belongs to the technical field of biomedicine and analysis, and provides an early screening model for esophageal cancer based on oral microbiota and a construction method therefor. The model uses the following oral microbiota as markers: Prevotella, Granulicatella, Rothia, Prevotellamassilia, Blautia, Abiotrophia, Peptostreptococcus, Actinomyces, Burkholderia, Akkermansia, Fudania, Kineothrix, Bacillus, Duncaniella, and Eisenbergiella. The disclosure detects early asymptomatic esophageal cancer patients by identifying non-invasive biomarkers.

The present disclosure relates to Akkermansia sp. and a product containing the Akkermansia sp. and use thereof. The Akkermansia is Akkermansia guangxiensis N21116 and N21169, and the accession numbers are respectively: GDMCC No: 62888 and GDMCC No: 62889. Akkermansia guangxiensis N21116 and N21169 are new species of Akkermansia sp., have resistance to human intestinal fluid, and have the effects of resisting oxidation, inhibiting tumor cell growth, and losing weight and reducing fat.

The application discloses a hybridoma cell strain 6F92E10, a monoclonal antibody thereof and application thereof, and belongs to the technical field of biotechnology.The application provides a hybridoma cell strain secreting an anti-mucinophilic Akkermansia monoclonal antibody.The antibody secreted by the hybridoma cell strain only combines with AKKermansia and does not cross-react with other common intestinal bacteria.In addition, the application solves how to detect the adhesion and colonization of mucinophilic Akkermansia in the colon of a mouse by using the prepared monoclonal antibody through an indirect immunofluorescence localization experiment, and expands the application range of the antibody.

The present invention relates to Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.

This invention belongs to the field of anti-allergy functional food technology, specifically relating to an anti-allergy composition containing inactivated Akkermansia myxophilus. Existing anti-allergy drugs have side effects. The composition of this invention contains inactivated Akkermansia myxophilus, quercetin, vitamin C, and zinc. This invention can improve allergic rhinitis, alleviate eczema symptoms, and improve allergic constitution by regulating immune balance and inhibiting histamine release. The composition of this invention is stable at room temperature and can be formulated into powder or chewable tablets.

The invention belongs to the technical field of microorganisms, and discloses a new application of ackermania martensii and a new strain Amass-2. The strain is safe, has no toxic factors, and has the functions of reducing cholesterol, inhibiting fat synthesis and reducing body weight.

The invention provides application of astragalus mongholicus fermentation liquor in prevention and treatment of lung cancer, and belongs to the technical field of traditional Chinese medicine fermentation. The prepared astragalus membranaceus fermentation liquor can reduce tumor volume, increase body weight, regulate body immunity, regulate intestinal flora, specifically enrich Akkermansia bacteria and promote biosynthesis of short-chain fatty acid, and effectively prevent and treat lung cancer. Meanwhile, liver and kidney injury and immune organ injury in the lung cancer can also be protected.

Provided herein are methods for selecting a subject with a seizure disorder for treatment, as well as methods of treating the subject, determining the efficacy of the treatment, and adjusting the treatment dosage and frequency. In some aspects, provided herein are methods of treating seizures in a subject by administering to the subject a composition comprising bacteria of the Akkermansia (Akk) and Parabacteroides (Pb) genera.

This invention discloses the application of Akkermansia in the preparation of drugs for the prevention and treatment of avian infectious bronchitis virus (AIB). Through research, this invention has found that Akkermansia can improve the survival rate of chickens infected with AIB and inhibit the replication of AIB. This demonstrates that Akkermansia has important applications in the preparation of drugs for the prevention and / or treatment of AIB infection, providing a new solution for the treatment of AIB infection, and can be specifically applied in drugs or feed additives for combating AIB infection.

The invention belongs to the field of microorganisms and medicine health care, and relates to an ackermania muciniphila strain and application thereof, the preservation number of the ackermania muciniphila strain is CGMCC (China General Microbiological Culture Collection Center) No.34370, and a 16SrDNA (Deoxyribose Nucleic Acid) sequence of the ackermania muciniphila strain has 93% similarity with a sequence shown as SEQ ID NO: 1. The new ackermania muciniphila strain (AKKBC300) is separated from a healthy human body and has good safety; good tolerance to low pH value and bile salt is shown in vitro, and it is indicated that the compound can reach the intestinal tract through the upper digestive tract and play a role; according to the present invention, genomics analysis results prove that the bacterial strain contains the gene Akkermansia BC00573 with high homology with the known probiotic functional protein Amuc1100, such that the molecular basis is provided;

A means for controlling growth of any bacteria selected from the group consisting of bacteria of the genus Faecalibacterium, bacteria of the genus Akkermansia, bacteria of the genus Blautia, bacteria of the genus Subdoligranulum, bacteria of the genus Bilophila, and bacteria of the genus Sutterella in the intestinal tract is provided. An object of the present invention is to provide a novel material that can control growth of bacteria of the genus Faecalibacterium. There is provided a composition for controlling growth of target bacteria in intestinal bacterial microbiota, which contains any selected from the group consisting of a human milk oligosaccharide and a constituent sugar of a human milk oligosaccharide.

The present application relates to the field of microorganisms, in particular to a mucinophilic Akkermansia strain and application thereof, the mucinophilic Akkermansia has a preservation number of CCTCC NO: M 20241304.The mucinophilic Akkermansia AKK-86 of the present application has good effects of promoting iron absorption, improving iron metabolism, and relieving intestinal inflammation.In addition, the mucinophilic Akkermansia of the present application can also promote the production of GLP-1, and has potential application in reducing blood sugar and weight loss products.

The invention discloses a co-culture method of Ackerman's bacteria and animal bifidobacterium lactis. The co-culture method comprises the following steps: (1) carrying out recovery culture on Ackerman's bacteria twice by using a BHI culture medium; (2) resuscitating the animal bifidobacterium lactis BB-12 twice by using an MRS culture medium to obtain an animal bifidobacterium lactis culture; and (3) respectively and sequentially centrifuging and washing cultures obtained in the step (1) and the step (2) with sterile PBS, and simultaneously inoculating the cultures into a whey protein hydrolysate culture medium for anaerobic culture. According to the method disclosed by the invention, ackermania and bifidobacterium lactis are co-cultured, so that lactose in a culture medium is fully utilized, and meanwhile, the product has the functions of two strains.

The present invention relates to Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.

This invention belongs to the field of anti-aging functional food technology, specifically relating to an anti-aging and longevity composition containing inactivated Akkermansia myxophilus. Existing anti-aging products are mostly single-ingredient products. The composition of this invention contains inactivated Akkermansia myxophilus, NMN, coenzyme Q10, resveratrol, and astaxanthin. This invention achieves the effects of delaying aging, improving muscle strength, and enhancing cognitive function by repairing the intestinal barrier, increasing NAD+ levels, and activating longevity pathways. The composition of this invention is stable at room temperature and can be formulated into capsules or powder.

The invention relates to an application of inactivated ackermania muciniphila Akk09 in preparation of a postbiotic preparation for controlling body weight and improving obesity. The preservation number of the ackermania muciniphila Akk09 is CCTCC (China Center For Type Culture Collection) NO: M 20242401. According to the present invention, the new use of the Ackermania muciniphila Akk09 is developed, the research basis is provided for the wide application of the Ackermania muciniphila Akk09, the brand new strategy for controlling body weight and improving obesity is developed, the inactivated Ackermania muciniphila Akk09 strain has significant effects on controlling body weight and improving obesity, and the inactivated Ackermania muciniphila Akk09 strain has significant application prospects. The Ackermania muciniphila Akk09 strain is a probiotic, the safety of the product is high, and the resistance is not easy to generate.

The application belongs to the field of biological detection, and particularly relates to a specific monoclonal antibody of an AKK bacterial efficacy protein Amuc_1100, a kit, a detection method and application thereof. The antibody pair is 3E10 and 2F7 monoclonal antibodies, the heavy chain and light chain variable region amino acid sequences of 3E10 are SEQ ID NO. 2 and SEQ ID NO. 4, and the heavy chain and light chain variable region amino acid sequences of 2F7 are SEQ ID NO. 6 and SEQ ID NO. 8. The antibody pair has high specificity and high affinity, a colloidal gold rapid detection kit and a double antibody sandwich ELISA quantitative detection kit based on the antibody pair realize rapid screening and accurate quantification of the Amuc_1100 protein, have good linearity, high precision and excellent accuracy, and can be used for detection of the protein in mucoid Akkermansia and quality control and activity evaluation of related probiotic preparations, thereby providing key technical support for related basic research and industrial application.

The application discloses a kind of improvement Akkermansia muciniphila The application discloses a starch-based feed for improving bacterial abundance, and belongs to the technical field of functional food. Experimental results show that the starch-based feed can significantly reverse the bacterial flora disorder of mice: PCoA analysis shows that it can restore the overall structure of the disordered bacterial flora to a healthy state; specifically, it improves the ratio of disordered Firmicutes / Bacteroidetes, promotes the proliferation of beneficial bacteria Akkermansia muciniphila, and inhibits the growth of conditional pathogenic bacteria, and the regulatory effect shows a dose-dependent manner. Therefore, the modified starch-based feed is a potential functional food raw material for regulating intestinal flora.